- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT07846969
Assessment of Vitiligo Lesions Using Polarized Dermoscopy, Sub-Ultraviolet Reflectance Dermoscopy, and Ultraviolet Dermoscopy
Evaluation of Morphological Findings Related to Activity, Stability, and Repigmentation in Vitiligo Lesions Using Polarized Dermoscopy, Sub-Ultraviolet Reflectance Dermoscopy, and Ultraviolet Fluorescence Dermoscopy: A Cross-Sectional Observational Imaging Study
The goal of this observational study is to learn how different close-up skin imaging methods show vitiligo spots in adults with vitiligo. The study will look at skin changes that may be related to whether a vitiligo spot is active, stable, or gaining color again.
The main question it aims to answer is: Can special light-based imaging methods show useful details of vitiligo spots differently than regular polarized dermoscopy?
Participants will have vitiligo spots photographed during one study visit. Researchers will take images using polarized dermoscopy, sub-ultraviolet reflectance imaging, and ultraviolet fluorescence dermoscopy. Dermatologists will later review the coded images and score how clearly selected skin features can be seen.
The study will not change participants' treatment. It will not include blood tests, biopsy, injections, or any other invasive procedure.
Studieoversikt
Status
Forhold
Detaljert beskrivelse
This is a single-center, cross-sectional observational imaging study in patients with clinically diagnosed vitiligo.
During a single study visit, demographic and clinical information will be recorded, including disease duration, recent disease course, current treatment status, and patient-reported changes in selected lesions. One to three clinically suitable vitiligo lesions will be included in the main assessment dataset for each participant. Genital lesions will not be evaluated due to practical imaging limitations, hygiene considerations, and participant comfort.
Each selected lesion will be imaged using the Casio DZ-D100-AEA device, which allows simultaneous acquisition of digital contact polarized dermoscopy, digital contact non-polarized dermoscopy, and sub-ultraviolet reflectance dermoscopy images from the same lesion area with a single image capture. This approach is intended to improve within-lesion comparability between polarized dermoscopy and sub-ultraviolet reflectance dermoscopy. Non-polarized images will be obtained as an automatic device output but will not be included in the routine analysis. Ultraviolet fluorescence dermoscopy images will be obtained from the same selected lesion using the DermLite DL5 handheld ultraviolet dermoscope with a smartphone adapter.
For each participant, one lesion will be designated as the index lesion for the primary analysis. If available, the second and third lesions in the main assessment dataset may be used for secondary and exploratory analyses. In participants with more than three imaged lesions, additional lesion images beyond the lesions retained in the main assessment dataset will be assigned to a separate exploratory/calibration image pool and will not be included in the formal main assessment dataset.
The allocation of lesions to the main assessment dataset or the exploratory/calibration pool will be completed before formal image scoring. When more than three lesions are available from a participant, lesions with clearer recent clinical history regarding activity, stability, or repigmentation will be preferentially retained in the main assessment dataset. If several lesions have similarly clear clinical information, allocation will aim to preserve representation of active/progressive, stable, and repigmented/regressive lesions when possible.
The exploratory/calibration image pool will be used for initial exploratory review, refinement of morphological terminology, preparation of evaluator training material, and calibration of scoring rules. These images will not be used as confirmatory evidence for the primary analysis.
Morphological assessment items will be developed from the literature and refined through the calibration process. This process will be used to standardize terminology and scoring rules among dermatologist evaluators before formal image evaluation.
After the scoring form is finalized, coded images from the main assessment dataset will be evaluated by dermatologist evaluators using a 0-3 visibility scoring system. To reduce observer bias, images will be presented without participant identity, lesion code, clinical lesion category, treatment information, or clinical history.
Complete blinding to imaging modality may not be possible because the imaging modalities have characteristic color and light features. This will be considered a methodological limitation. However, the coded and randomized image review process is intended to reduce recognition bias, recall bias, and assessment-order bias.
Studietype
Registrering (Antatt)
Kontakter og plasseringer
Studiekontakt
- Navn: Sueda Şanlı Arıkan, Dermatology Resident Physician
- Telefonnummer: +90 5362483355
- E-post: sueda.sanli.md@gmail.com
Studiesteder
-
-
-
Istanbul, Tyrkia (Türkiye)
- Rekruttering
- University of Health Sciences Istanbul Training and Research Hospital
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Prøvetakingsmetode
Studiepopulasjon
Adult patients with clinically diagnosed vitiligo who attend the dermatology outpatient clinic and have at least one clinically suitable non-genital vitiligo lesion for dermoscopic imaging.
Beskrivelse
Inclusion Criteria:
- Adults aged 18 years or older
- Clinical diagnosis of vitiligo
- Presence of at least one clinically suitable non-genital vitiligo lesion for dermoscopic imaging
- Ability and willingness to provide written informed consent
Exclusion Criteria:
- Uncertain clinical diagnosis of vitiligo or presence of another hypopigmented or depigmented disorder that may interfere with lesion evaluation
- Absence of any clinically suitable non-genital vitiligo lesion for imaging
- Inability to cooperate with the imaging procedure
- Refusal or inability to provide written informed consent
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Observasjonsmodeller: CASE_ONLY
- Tidsperspektiver: CROSS_SECTIONAL
Kohorter og intervensjoner
Gruppe / Kohort |
|---|
|
Adults With Vitiligo
Adult participants with clinically diagnosed vitiligo who will undergo close-up dermoscopic imaging of one to three clinically suitable vitiligo lesions during a single study visit |
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Comparison of total visibility scores between polarized dermoscopy and sub-ultraviolet reflectance dermoscopy
Tidsramme: Day 1
|
For each participant, the index lesion will be evaluated in polarized dermoscopy and sub-ultraviolet reflectance dermoscopy images. Selected lesion morphology items on the finalized scoring form will be scored from 0 to 3, where 0 indicates absent or not visible and 3 indicates clearly visible. A total visibility score will be calculated for each modality, and the paired within-lesion difference between the two modalities will be analyzed. |
Day 1
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Visibility scores of individual lesion morphology items across imaging modalities
Tidsramme: Day 1
|
Individual lesion morphology items on the finalized scoring form will be evaluated using a 0-3 visibility scoring system, where 0 indicates absent or not visible and 3 indicates clearly visible. Scores will be assessed across polarized dermoscopy, sub-ultraviolet reflectance dermoscopy, and ultraviolet fluorescence dermoscopy. |
Day 1
|
|
Detection rates of individual lesion morphology items after dichotomization of visibility scores
Tidsramme: Day 1
|
Visibility scores will be dichotomized for each lesion morphology item, with a score of 0 defined as not detected and scores of 1, 2, or 3 defined as detected. Detection rates will be calculated and compared across imaging modalities. |
Day 1
|
|
Assessment of ultraviolet and sub-ultraviolet optical findings
Tidsramme: Day 1
|
Optical findings observed in sub-ultraviolet reflectance dermoscopy and ultraviolet fluorescence dermoscopy will be assessed using the finalized scoring form. Depending on the finalized assessment item, findings may be recorded either as 0-3 visibility scores or as binary detection variables. These findings may include lesion-to-surrounding skin contrast, border visibility, perifollicular optical changes, and intralesional heterogeneity. |
Day 1
|
|
Inter-rater agreement for lesion morphology assessment
Tidsramme: Through completion of image evaluation, up to 6 months
|
Agreement between dermatologist evaluators will be assessed for visibility scores and/or binary detection of lesion morphology items using appropriate agreement statistics. |
Through completion of image evaluation, up to 6 months
|
Samarbeidspartnere og etterforskere
Etterforskere
- Studiestol: Ayşe Esra Koku Aksu, Professor, University of Health Sciences Istanbul Training and Research Hospital, Dermatology Department
Studierekorddatoer
Studer hoveddatoer
Studiestart (Faktiske)
Primær fullføring (Antatt)
Studiet fullført (Antatt)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Nøkkelord
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- IstanbulTRH-DERM-VITSUV-2026
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .